Get the Stockscreener App
2.735
1.67%
0.045
Sonoma Pharmaceuticals Inc stock is traded at $2.735, with a volume of 2,110.
It is up +1.67% in the last 24 hours and down -2.67% over the past month.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
See More
Previous Close:
$2.69
Open:
$2.71
24h Volume:
2,110
Relative Volume:
0.01
Market Cap:
$3.60M
Revenue:
$12.31M
Net Income/Loss:
$-5.08M
P/E Ratio:
-1.7993
EPS:
-1.52
Net Cash Flow:
$-5.20M
1W Performance:
-0.55%
1M Performance:
-2.67%
6M Performance:
-41.76%
1Y Performance:
-24.86%
1-Day Range:
$2.71
$2.75
1-Week Range:
$2.6602
$2.845
52-Week Range:
$2.44
$9.374
Sonoma Pharmaceuticals Inc Stock (SNOA) Company Profile
Name
Sonoma Pharmaceuticals Inc
Sector
Phone
800-759-9305
Address
5445 CONESTOGA COURT, SUITE 150, BOULDER, CA
Compare SNOA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNOA
Sonoma Pharmaceuticals Inc
|
2.75 | 3.60M | 12.31M | -5.08M | -5.20M | -0.94 |
|
ZTS
Zoetis Inc
|
163.93 | 73.51B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.52 | 43.13B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.28 | 41.98B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.12 | 24.97B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.55 | 14.86B | 15.05B | -883.30M | 1.89B | -0.74 |
Sonoma Pharmaceuticals Inc Stock (SNOA) Latest News
Despite Fast-paced Momentum, Sonoma Pharmaceuticals (SNOA) Is Still a Bargain Stock - MSN
Sonoma Pharmaceuticals, Inc. Announces Two Singapore Approvals for Microcyn for the Treatment of Atopic Dermatitis and Hypertrophic / Keloid Scars - Marketscreener.com
Keloid Treatment Market Top PlayersNovartis AG, Sensus - openPR
Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Crosses Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
SNOA stock touches 52-week low at $2.44 amid market challenges - Investing.com
SNOA stock touches 52-week low at $2.44 amid market challenges By Investing.com - Investing.com South Africa
Sonoma Pharmaceuticals (SNOA) Stock Surges Amid Market Fluctuati - GuruFocus.com
SNOA Stock Hits 52-Week Low at $2.47 Amid Market Challenges - Investing.com Canada
SNOA Stock Hits 52-Week Low at $2.47 Amid Market Challenges By Investing.com - Investing.com South Africa
Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices - AccessWire
Sonoma Pharmaceuticals (SNOA) Stock Declines Amid Market Activit - GuruFocus.com
Sonoma Pharmaceuticals (STU:O8Z) PE Ratio : At Loss (As of Nov. 30, 2024) - GuruFocus.com
SNOA (Sonoma Pharmaceuticals) Debt-to-Equity : 0.05 (As of Sep. 2024) - GuruFocus.com
Sonoma Pharmaceuticals (STU:O8Z) Growth Rank : 2 (As of Nov. 26, 2024) - GuruFocus.com
Eye Care Product Lines - Trend Hunter
Alkermes (ALKS) Stock Surges Over 5% Amid Strong Financial Perfo - GuruFocus.com
Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States - BioSpace
Sonoma Pharmaceuticals, Inc. Receives New FDA 510(K) Clearance for Microcyn(R)-Based Wound Care Hydrogel - Marketscreener.com
Scar Treatment Market Detailed In New Research Report 2024 | - openPR
Sonoma Pharmaceuticals ends agreement with EMC Pharma - Investing.com
Merck (MRK) Stock Surges Amid Industry Layoff Trends - GuruFocus.com
Sonoma Pharmaceuticals ends agreement with EMC Pharma By Investing.com - Investing.com Australia
Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in - PharmiWeb.com
Amarin (AMRN) Stock Surges Amid Mixed Industry Performance - GuruFocus.com
Sonoma Pharmaceuticals Announces Relaunch of - One News Page
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 - Marketscreener.com
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.86% - MSN
Animal Wound Care Market to Exhibit a Remarkable CAGR of 7.9% - openPR
AMGN Stock Drops 5% Amid Industry Decline and Earnings Report - GuruFocus.com
Siga Technologies (SIGA) Sees Significant Stock Decline Amidst P - GuruFocus.com
Sonoma Pharmaceuticals gains FDA clearance for hydrogel By Investing.com - Investing.com Australia
Sonoma Pharmaceuticals (NASDAQ:SNOA) Share Price Passes Above Two Hundred Day Moving Average – Here’s Why - Defense World
Sonoma Pharmaceuticals gains FDA clearance for hydrogel - Investing.com India
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel - AccessWire
Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews
Sonoma Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Sonoma Pharmaceuticals Inc. (SNOA) Quarterly 10-Q Report - Quartz
Sonoma Pharmaceuticals Inc (SNOA) Quarterly 10-Q Report - Quartzy
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results - AccessWire
Certain Options of Sonoma Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 29-JAN-2020. - Marketscreener.com
Certain Restricted Stock Units of Sonoma Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 29-JAN-2020. - Marketscreener.com
Certain Warrants of Sonoma Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 29-JAN-2020. - Marketscreener.com
Certain Preferred stock of Sonoma Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 29-JAN-2020. - Marketscreener.com
Sonoma Pharmaceuticals Inc Stock (SNOA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.55%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):